×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
The Legal, Ethical, and Commercial Issues Impacting the Development and Accessibility of Pediatric Medicines
Session Chair(s)
Marie Manley
Partner, Head of EU and UK Life Sciences (UK)
Sidley Austin LLP, United Kingdom
This forum will assess the European Commission’s five-year report on the performance of the pediatric regulation and identify from a legal and ethical dimension the strengths and weaknesses in the operational structure.
This forum has been developed by the DIA Legal Affairs and Ethics and the Medicines Lifecycle Communities.
Learning Objective : Assess the ethical considerations relevant to the EU legal framework on pediatric medicines; Describe the EU legal framework governing pediatric clinical research; Describe the system of rewards and incentives within the EU Pediatric Regulation; Identify benefits and weaknesses of the existing regulatory system; Consider if the current legal framework is appropriate to govern pediatric medicine.
Speaker(s)
What Have Been the Benefits and Lessons Learned After Five Years of the Pediatric Regulation?
Marie Manley
Sidley Austin LLP, United Kingdom
Partner, Head of EU and UK Life Sciences (UK)
Impact Of The EU Pediatric Regulation
Klaus Rose, MD, MS
klausrose Consulting, Switzerland
Chief Executive Officer
The EU Pediatric Regulation: The Regulator's Perspective
Karl-Heinz Huemer, MD, PhD
Austrian Medicines and Medical Devices Agency (AGES), Austria
Clinical Assessor, Scientific Office
Have an account?